Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Entero Therapeutics, Inc. (ENTO) had Normalized Income after Taxes of $-0.67M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-1.08M |
|
-- |
|
-- |
|
$0.64M |
|
$-0.64M |
|
$-0.04M |
|
$-0.67M |
|
$-0.67M |
|
$-0.67M |
|
$-0.67M |
|
$-1.00M |
|
|
Normalized Income after Taxes |
$-0.67M |
$-0.64M |
|
$-0.64M |
|
4.76M |
|
4.76M |
|
$-0.23 |
|
$-0.23 |
|
| Balance Sheet Financials | |
$83.32M |
|
-- |
|
$1.74M |
|
$85.06M |
|
$29.68M |
|
-- |
|
-- |
|
$29.68M |
|
$-6.30M |
|
$53.70M |
|
$55.38M |
|
4.77M |
|
| Cash Flow Statement Financials | |
$-0.87M |
|
-- |
|
$0.70M |
|
$0.18M |
|
$0.01M |
|
$-0.17M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.81 |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.87M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
10.72% |
|
-1.26% |
|
-0.79% |
|
-1.22% |
|
$11.62 |
|
$-0.18 |
|
$-0.18 |
|